Catalent, Inc. - Understand $ctlt stock

$CTLT Market Cap: $11.22 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$3.398B

TTM

Gross Margin

22.84%

TTM

Net Earnings

-$207.0M

TTM

Current Assets

$2.917B

Q2 2025

Current Liabilities

$1.098B

Q2 2025

Current Ratio

265.66%

Q2 2025

Total Assets

$10.51B

Q2 2025

Total Liabilities

$5.733B

Q2 2025

Book Value

$4.775B

Q2 2025

Cash

P/E

-54.23

Nov 29, 2024 EST

Free Cash Flow

$81.00M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	$4.381B	$4.276B	$4.828B	$3.998B	$3.094B	$2.518B	$2.463B	$2.075B	$1.848B	$1.831B	$1.828B	$1.800B	$1.695B	$1.532B	$1.480B
YoY Change	2.46%	-11.43%	20.76%	29.22%	22.88%	2.22%	18.7%	12.3%	0.94%	0.17%	1.52%	6.22%	10.64%	3.47%	5.83%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	$4.381B	$4.276B	$4.828B	$3.998B	$3.094B	$2.518B	$2.463B	$2.075B	$1.848B	$1.831B	$1.828B	$1.800B	$1.695B	$1.532B	$1.480B
Cost Of Revenue	$3.428B	$3.216B	$3.188B	$2.646B	$2.111B	$1.713B	$1.711B	$1.421B	$1.261B	$1.216B	$1.229B	$1.232B	$1.136B	$1.030B	$1.040B
Gross Profit	$953.0M	$1.060B	$1.640B	$1.352B	$983.0M	$805.0M	$752.6M	$654.6M	$587.6M	$615.3M	$598.6M	$568.6M	$558.6M	$502.1M	$440.9M
Gross Profit Margin	21.75%	24.79%	33.97%	33.82%	31.77%	31.97%	30.55%	31.54%	31.79%	33.61%	32.75%	31.58%	32.96%	32.78%	29.78%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Selling, General & Admin	$935.0M	$831.0M	$844.0M	$687.0M	$577.0M	$512.0M	$464.8M	$402.6M	$358.1M	$337.3M	$334.8M	$340.6M	$348.1M	$261.8M	$270.1M
YoY Change	12.52%	-1.54%	22.85%	19.06%	12.7%	10.15%	15.45%	12.43%	6.17%	0.75%	-1.7%	-2.15%	32.96%	-3.07%	11.89%
% of Gross Profit	98.11%	78.4%	51.46%	50.81%	58.7%	63.6%	61.76%	61.5%	60.94%	54.82%	55.93%	59.9%	62.32%	52.14%	61.26%
Research & Development	$17.00M	$18.00M	$23.00M	$21.00M	$21.00M	$19.00M	$6.300M	$7.000M	$7.600M	$12.20M	$17.50M	$14.50M	$16.90M	$26.50M
YoY Change	-5.56%	-21.74%	9.52%	0.0%	10.53%	201.59%	-10.0%	-7.89%	-37.7%	-30.29%	20.69%	-14.2%	-36.23%
% of Gross Profit	1.78%	1.7%	1.4%	1.55%	2.14%	2.36%	0.84%	1.07%	1.29%	1.98%	2.92%	2.55%	3.03%	5.28%
Depreciation & Amortization	$489.0M	$422.0M	$378.0M	$289.0M	$254.0M	$229.0M	$190.1M	$146.5M	$140.6M	$140.8M	$142.9M	$152.2M	$129.7M
YoY Change	15.88%	11.64%	30.8%	13.78%	10.92%	20.46%	29.76%	4.2%	-0.14%	-1.47%	-6.11%	17.35%
% of Gross Profit	51.31%	39.81%	23.05%	21.38%	25.84%	28.45%	25.26%	22.38%	23.93%	22.88%	23.87%	26.77%	23.22%
Operating Expenses	$1.015B	$987.0M	$867.0M	$708.0M	$598.0M	$531.0M	$464.8M	$402.6M	$358.1M	$337.3M	$334.8M	$340.6M	$348.1M	$288.3M	$270.1M
YoY Change	2.84%	13.84%	22.46%	18.39%	12.62%	14.24%	15.45%	12.43%	6.17%	0.75%	-1.7%	-2.15%	20.74%	6.74%	11.89%
Operating Profit	-$62.00M	$73.00M	$756.0M	$828.0M	$394.0M	$274.0M	$268.9M	$234.2M	$217.8M	$259.9M	$240.9M	$204.4M	$198.0M	$213.8M	$170.8M
YoY Change	-184.93%	-90.34%	-8.7%	110.15%	43.8%	1.9%	14.82%	7.53%	-16.2%	7.89%	17.86%	3.23%	-7.39%	25.18%	22.61%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Interest Expense	-$254.0M	-$184.0M	-$156.0M	-$115.0M	-$123.1M	-$110.4M	-$106.8M	-$94.30M	-$75.90M	-$102.6M	-$163.1M	-$203.1M	-$183.0M	-$165.4M	-$161.0M
YoY Change	38.04%	17.95%	35.65%	-6.58%	11.5%	3.37%	13.26%	24.24%	-26.02%	-37.09%	-19.69%	10.98%	10.64%	2.73%	-11.54%
% of Operating Profit		-252.05%	-20.63%	-13.89%	-31.24%	-40.29%	-39.72%	-40.26%	-34.85%	-39.48%	-67.7%	-99.36%	-92.42%	-77.36%	-94.26%
Other Income/Expense, Net	-$24.00M	$6.000M	-$28.00M	-$3.000M	-$8.000M	-$3.000M	-$5.500M	-$8.500M	$15.60M	-$42.40M	-$10.40M	-$25.10M	$3.800M	-$26.10M	$7.300M
YoY Change	-500.0%	-121.43%	833.33%	-62.5%	166.67%	-45.45%	-35.29%	-154.49%	-136.79%	307.69%	-58.57%	-760.53%	-114.56%	-457.53%	-57.06%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Pretax Income	-$1.027B	-$315.0M	$605.0M	$715.0M	$260.0M	$36.00M	$13.30M	$5.000M	$60.00M	$25.80M	-$75.60M	-$124.9M	-$402.1M	-$5.400M	-$215.4M
YoY Change	226.03%	-152.07%	-15.38%	175.0%	622.22%	170.68%	166.0%	-91.67%	132.56%	-134.13%	-39.47%	-68.94%	7346.3%	-97.49%	19.34%
Income Tax	$16.00M	-$83.00M	$86.00M	$130.0M	$39.00M	$23.00M	$68.40M	$25.80M	$33.70M	-$97.70M	$49.50M	$27.00M	$500.0K	$23.70M	$21.90M
% Of Pretax Income			14.21%	18.18%	15.0%	63.89%	514.29%	516.0%	56.17%	-378.68%
Net Earnings	-$1.066B	-$232.0M	$519.0M	$585.0M	$221.0M	$137.0M	$83.60M	$109.8M	$111.5M	$212.2M	$16.20M	-$49.60M	-$24.40M	-$54.00M	-$289.6M
YoY Change	359.48%	-144.7%	-11.28%	164.71%	61.31%	63.88%	-23.86%	-1.52%	-47.46%	1209.88%	-132.66%	103.28%	-54.81%	-81.35%	-6.0%
Net Earnings / Revenue	-24.33%	-5.43%	10.75%	14.63%	7.14%	5.44%	3.39%	5.29%	6.03%	11.59%	0.89%	-2.76%	-1.44%	-3.53%	-19.56%
Basic Earnings Per Share	-$5.76	-$1.42	$2.85	$3.15	$1.16	$0.92	$0.64	$0.88	$0.89	$1.77	$0.22	-$0.66	-$0.33
Diluted Earnings Per Share	-$5.76	-$1.28	$2.84	$3.11	$1.14	$0.90	$0.63	$0.87	$0.89	$1.75	$0.21	-$0.66	-$0.32	-$460.4K	-$2.469M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$289.0M	$280.0M	$538.0M	$967.0M	$953.2M	$345.4M	$410.2M	$306.9M	$131.6M	$151.3M	$74.40M	$106.4M	$139.0M
YoY Change	3.21%	-47.96%	-44.36%	1.45%	175.97%	-15.8%	33.66%	133.21%	-13.02%	103.36%	-30.08%	-23.45%
Cash & Equivalents	$289.0M	$280.0M	$449.0M	$896.0M	$953.2M	$345.4M	$410.2M	$288.3M	$131.6M	$151.3M	$74.40M	$106.4M	$139.0M
Short-Term Investments			$89.00M	$71.00M			$0.00	$18.60M
Other Short-Term Assets	$813.0M	$658.0M	$205.0M	$165.0M	$93.40M	$68.70M	$54.10M	$67.40M	$78.20M	$69.40M	$62.10M	$78.00M	$97.00M
YoY Change	23.56%	220.98%	24.24%	76.66%	35.95%	26.99%	-19.73%	-13.81%	12.68%	11.76%	-20.38%	-19.59%
Inventory	$574.0M	$764.0M	$724.0M	$593.0M	$346.9M	$265.3M	$220.2M	$196.7M	$165.6M	$144.4M	$147.3M	$136.7M	$130.4M
Prepaid Expenses
Receivables	$921.0M	$977.0M	$1.449B	$1.193B	$899.5M	$716.4M	$555.8M	$488.8M	$414.8M	$372.4M	$403.7M	$358.0M	$338.3M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.597B	$2.679B	$2.916B	$2.918B	$2.293B	$1.396B	$1.240B	$1.060B	$790.2M	$737.5M	$687.5M	$679.1M	$704.7M
YoY Change	-3.06%	-8.13%	-0.07%	27.26%	64.28%	12.54%	17.03%	34.12%	7.15%	7.27%	1.24%	-3.63%
Property, Plant & Equipment	$3.643B	$3.699B	$3.220B	$2.608B	$2.002B	$1.537B	$1.271B	$995.9M	$905.8M	$885.2M	$873.0M	$814.5M	$809.7M
YoY Change	-1.51%	14.88%	23.47%	30.26%	30.29%	20.94%	27.58%	9.95%	2.33%	1.4%	7.18%	0.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.513B	$4.404B	$305.0M	$250.0M	$122.0M	$99.80M	$78.10M	$81.40M	$104.6M	$85.40M	$75.00M	$60.30M	$177.0M
YoY Change	-20.23%	1343.93%	22.0%	104.92%	22.24%	27.78%	-4.05%	-22.18%	22.48%	13.87%	24.38%	-65.93%
Total Long-Term Assets	$7.156B	$8.103B	$7.591B	$6.194B	$5.484B	$4.788B	$3.291B	$2.395B	$2.301B	$2.401B	$2.403B	$2.270B	$2.434B
YoY Change	-11.69%	6.74%	22.55%	12.96%	14.52%	45.5%	37.43%	4.07%	-4.16%	-0.08%	5.83%	-6.73%
Total Assets	$9.753B	$10.78B	$10.51B	$9.112B	$7.777B	$6.184B	$4.531B	$3.454B	$3.091B	$3.138B	$3.090B	$2.950B	$3.139B
YoY Change
Accounts Payable	$361.0M	$427.0M	$421.0M	$385.0M	$321.0M	$255.8M	$192.1M	$163.2M	$143.7M	$128.2M	$148.1M	$150.8M	$134.2M
YoY Change	-15.46%	1.43%	9.35%	19.94%	25.49%	33.16%	17.71%	13.57%	12.09%	-13.44%	-1.79%	12.37%
Accrued Expenses	$622.0M	$544.0M	$385.0M	$401.0M	$303.8M	$174.7M	$186.1M	$171.6M	$134.8M	$150.7M	$170.1M	$156.6M	$180.3M
YoY Change	14.34%	41.3%	-3.99%	31.99%	73.9%	-6.13%	8.45%	27.3%	-10.55%	-11.41%	8.62%	-13.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$59.10M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change				-100.0%
Long-Term Debt Due	$48.00M	$536.0M	$31.00M	$75.00M	$13.80M	$76.50M	$71.90M	$24.60M	$27.70M	$23.80M	$25.20M	$35.00M	$43.20M
YoY Change	-91.04%	1629.03%	-58.67%	443.48%	-81.96%	6.4%	192.28%	-11.19%	16.39%	-5.56%	-28.0%	-18.98%
Total Short-Term Liabilities	$1.031B	$1.507B	$1.072B	$1.196B	$893.2M	$670.7M	$576.9M	$469.0M	$391.2M	$399.0M	$453.0M	$410.3M	$439.3M
YoY Change	-31.59%	40.58%	-10.37%	33.9%	33.17%	16.26%	23.01%	19.89%	-1.95%	-11.92%	10.41%	-6.6%
Long-Term Debt	$4.857B	$4.313B	$4.171B	$3.166B	$2.945B	$2.883B	$2.649B	$2.055B	$1.833B	$1.857B	$2.685B	$2.657B	$2.640B
YoY Change	12.61%	3.4%	31.74%	7.5%	2.16%	8.81%	28.92%	12.13%	-1.3%	-30.85%	1.08%	0.62%
Other Long-Term Liabilities	$261.0M	$327.0M	$267.0M	$312.0M	$338.8M	$267.9M	$185.6M	$175.0M	$189.8M	$186.2M	$215.9M	$181.1M	$190.2M
YoY Change	-20.18%	22.47%	-14.42%	-7.91%	26.47%	44.34%	6.06%	-7.8%	1.93%	-13.76%	19.22%	-4.78%
Total Long-Term Liabilities	$5.118B	$4.640B	$4.438B	$3.478B	$3.284B	$3.151B	$2.835B	$2.230B	$2.023B	$2.043B	$2.901B	$2.838B	$2.831B
YoY Change	10.3%	4.55%	27.6%	5.91%	4.23%	11.14%	27.12%	10.26%	-1.01%	-29.58%	2.24%	0.25%
Total Liabilities	$6.149B	$6.147B	$5.712B	$4.838B	$4.271B	$3.896B	$3.444B	$2.731B	$2.455B	$2.504B	$3.461B	$3.360B	$3.490B
YoY Change	0.03%	7.62%	18.07%	13.27%	9.63%	13.11%	26.13%	11.23%	-1.96%	-27.65%	3.01%	-3.71%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Basic Shares Outstanding	181.0M shares	181.0M shares	176.0M shares	168.0M shares	150.0M shares	144.0M shares	131.2M shares	125.0M shares	124.8M shares	119.6M shares	75.05M shares	74.97M shares	74.88M shares
Diluted Shares Outstanding	181.0M shares	181.0M shares	178.0M shares	170.0M shares	152.0M shares	146.0M shares	133.2M shares	126.7M shares	125.9M shares	121.3M shares	76.12M shares	74.97M shares	75.38M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $11.225 Billion

About Catalent, Inc.

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 16,900 full-time employees. The company went IPO on 2014-07-31. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. The company also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. The company also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

Industry: Pharmaceutical Preparations Peers: BRISTOL MYERS SQUIBB CO Elanco Animal Health Inc Intra-Cellular Therapies, Inc. JOHNSON & JOHNSON Merck & Co., Inc. Organon & Co. PFIZER INC Royalty Pharma plc Viatris Inc Zoetis Inc.